Actively Recruiting
Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
Led by baotai Liang · Updated on 2025-09-08
96
Participants Needed
2
Research Sites
131 weeks
Total Duration
On this page
Sponsors
B
baotai Liang
Lead Sponsor
T
The First People Hospital of Nantong City
Collaborating Sponsor
AI-Summary
What this Trial Is About
The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although neoadjuvant androgen deprivation therapy combined with radical prostatectomy reduced the positive rate of surgical margins, it did not show statistically significant improvement in prostate-specific antigen (PSA). At the same time, few trials reported pathological complete response (pCR) and minimal residual lesion (MRD). The purpose of this project is to verify the therapeutic effect of homoharringtonine combined androgen deprivation in patients with locally advanced prostate cancer or oligometastatic prostate cancer before radical prostatectomy through a randomized controlled clinical trial, so as to find an effective treatment for locally advanced prostate cancer or oligometastatic prostate cancer.
CONDITIONS
Official Title
Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 85 years
- Histologically confirmed prostate cancer without small cell features
- Locally advanced prostate cancer (cT3-4) or metastatic prostate cancer with 5 or fewer oligometastases (bone or lymph node)
- ECOG performance status of 0 or 1
- Able to voluntarily provide informed consent and comply with treatment and follow-up
You will not qualify if you...
- Any previous or ongoing prostate cancer treatment, including radiotherapy, chemotherapy, or androgen deprivation therapy
- Previous prostatectomy surgery
- Presence of serious medical, mental, or psychological diseases that may interfere with treatment
- Allergy to the drugs used in the study
- Refusal to undergo radical prostatectomy
- Investigator's judgment deeming participant unsuitable for the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Zhongda Hospital
Nanjing, Jiangsu, China
Actively Recruiting
2
The First People Hospital of Nantong City
Nantong, Jiangsu, China
Actively Recruiting
Research Team
R
resident doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here